• Non-pregnant adults and children with type 1 diabetes, as defined in each individual study that were assessed in an outpatient setting (including hotel and diabetes camp settings) or under free-living conditions in their home and work environment.
Intervention
• Any closed-loop delivery system, defined as a system utilising a control algorithm, which autonomously increases and decreases insulin delivery based on real-time sensor glucose concentrations, assessed either during daytime, overnight period, or the day-and-night period.
Comparators
• Any type of insulin based therapy, including multiple daily injections (MDI), insulin pump therapy, sensor-augmented insulin pump therapy, sensor-augmented insulin pump with a low glucose suspend (LGS) feature.
Outcomes
Primary outcome: Proportion of time that glucose level was within the near normoglycaemic range (3.9 -10 mmol/l) (both overnight, and during a 24h period).
Secondary outcomes:
• % of time during day and night (24h) or night only that glucose level was below 3.9 mmol/l • % of time during day and night (24h) or night only that glucose level was above 10 mmol/l
• area under the curve (AUC) of glucose < 3.5 mmol/l
• low blood glucose index (LBGI)
• Mean blood glucose levels • HbA1c
• Insulin amount administered
Study design
Randomised controlled trials, with parallel group or cross-over design, irrespective of duration of intervention.
Information sources

Search strategy
Search strategy based only on the intervention (Closed-loop system) and a filter for randomised trials, to avoid missing potentially relevant studies, as recommended in the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in health care and the Cochrane Handbook. We will use search terms that have been identified from initial scoping searches, target references and browsing of database thesauri (i.e.
Medline MeSH and Embase Emtree). We have developed search strategies specifically for each database based on the search features and controlled vocabulary of every individual bibliographic database. We will search the following databases and resources (via relevant interfaces):
• Cochrane Database of Systematic Reviews (CDSR) (Wiley Online Library)
• Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley Online Library)
We will also look for completed and on-going trials by searching the NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/) trial registry.
We will impose no restrictions based on language or publication status. References identified will be imported in Endnote reference management software for de-duplication. Finally, we will export potentially eligible records to Covidence™ for further handling (screening and data extraction).
Study selection & data collection
All records will be screened via Covidence™, by two reviewers, working independently, and disagreements will be arbitrated by a senior team member. Initially, records will be screened at title and abstract level. Full texts for potentially eligible studies will be imported into Covidence™ and screened as described previously. Finally, we will extract data for the following variables: study and participant baseline characteristics, details for the interventions (i.e. single-hormone, algorithm utilised) and comparators, and clinical outcomes. Data will be extracted by two reviewers, using a piloted, data extraction form. Disagreements will be resolved by consensus or following discussion with a senior reviewer. For crossover studies that report their results as parallel group trials, we will use appropriate methodology to impute within-patient differences.
Study quality assessment
We will assess the methodological quality of included RCTs using the Cochrane Risk of Bias Tool. For crossover studies we will use a modified version to assess a series of methodological challenges that are linked with this specific design. We will use results for descriptive purposes to provide an evaluation of the overall quality of the included studies, but also to inform a sensitivity analysis. Quality assessment will be undertaken by two independent reviewers, and disagreements will be resolved by consensus or arbitrated by a third reviewer.
Data synthesis
Methods of analysis
We will combine data both from parallel group and cross-over studies if appropriate. We will calculate mean differences with 95% confidence intervals, using an inverse-variance weighted random effects model.
Subgroup analyses
Depending on accrued evidence, for the primary outcome we plan to conduct subgroup analyses based on mode of intervention (overnight or 24h use of closed-loop delivery system), and type of closed-loop (single vs dual-hormone closed-loop).
Sensitivity analyses
We will do sensitivity analysis for the primary outcome excluding trials at unclear or high risk of bias, trials conducted at other settings than home or hotel, and supervised trials.
Investigation of heterogeneity
We will assess presence of statistical heterogeneity by means of the chi-square-based Cochran Q test and the magnitude of heterogeneity by means of the I 2 statistic, with P values < 0.10 and I 2 > 50% respectively representing high heterogeneity. All analyses will be undertaken in Revman.
This protocol was submitted as a module assignment for the Systematic Review module for an MSc on Medical
Research Methodology at Aristotle University Thessaloniki, and internally peer reviewed. Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. 4
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
3, 4
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. Appendix 3
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). 4
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 4, appendix 4
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 4
Risk of bias in individual studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. reporting within studies). 5
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. 4-5
RESULTS
Study selection
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 5, Figure 1 Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. #30. #28 NOT #29
#31. #20 AND #30
Trial filter based on terms suggested by the Cochrane Handbook:
Lefebvre C, Manheimer E, Glanville J. We also extracted information for the following parameters for assessment of risk of bias for every individual trial:
• Sequence generation (or randomised treatment order for cross-over studies)
• Allocation concealment 
